Role of Ivabradine in reducing tachycardia mediated adverse outcomes in vasopressor supported septic shock

Calcutta national medical college0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. In age of 18 to 50 years,
•2. Patients who are admitted in intensive care units (both medical and surgical) and received intensive care management for ongoing and properly diagnosed septic shock, following any condition.
•3. Patients who obeyed the haemodynamic, haematological, cardiovascular, renal and other valued parameters used in diagnosing sepsis.
•4. Patients who showed active bacterial growth in blood culture and sensitivity
•5. Patients who had a significantly raised heart rate above 100/min

•1. Patients or their relatives refusing to give consent
•2. Patients who have a documented cardiac ailment from echocardiography findings. (ie. cardiac failure, previous infarction)
•3. Patients with Chronic kidney disease, DCLD
•4. Patients with documented neurologic disorder prior to sepsis
•5. Paediatric patients, Age <18 yrs.
•6. Patient requiring more than two vasopressors at a time for maintaining haemodynamics.
•7. Patients who had associated ARDS at the time of vasopressor initiation and requiring high PEEP.

发起方